Search results for "Kinetics"

showing 10 items of 2224 documents

Induction of the anti-ergotypic response.

1993

The injection of syngeneic activated T cells into rodents can induce a T cell response against activation markers of the T cells, ergotopes. The responding anti-ergotypic T cells have been shown to suppress experimental autoimmune encephalomyelitis (EAE). This paper reports the characteristics of the anti-ergotypic response. It was found that irradiated activated T cells were as good as untreated living activated T cells in inducing anti-ergotypic cells in vivo. Glutardialdehyde-fixed (0.3%) cells were poor stimulators in vivo and non-stimulatory in vitro. Dilution of glutardialdehyde to 0.003% before fixation preserved the stimulatory capacity in vitro. Fixation or irradiation of T cells a…

Adoptive cell transferCellular immunityT cellT-LymphocytesImmunologyDose-Response Relationship ImmunologicBiologyIn Vitro TechniquesLymphocyte ActivationEpitopeImmune systemIn vivomedicineImmunology and AllergyAnimalsAutoantibodiesProteinsGeneral MedicineT lymphocyteMolecular biologyIn vitroRatsKineticsmedicine.anatomical_structureSolubilityRats Inbred LewImmunologyFemaleInternational immunology
researchProduct

Subdominant CD8 T-Cell Epitopes Account for Protection against Cytomegalovirus Independent of Immunodomination▿ †

2008

ABSTRACTCytomegalovirus (CMV) infection continues to be a complication in recipients of hematopoietic stem cell transplantation (HSCT). Preexisting donor immunity is recognized as a favorable prognostic factor for the reconstitution of protective antiviral immunity mediated primarily by CD8 T cells. Furthermore, adoptive transfer of CMV-specific memory CD8 T (CD8-TM) cells is a therapeutic option for preventing CMV disease in HSCT recipients. Given the different CMV infection histories of donor and recipient, a problem may arise from an antigenic mismatch between the CMV variant that has primed donor immunity and the CMV variant acquired by the recipient. Here, we have used the BALB/c mouse…

Adoptive cell transferMuromegalovirusImmunologyEpitopes T-LymphocyteBiologyCD8-Positive T-LymphocytesMajor histocompatibility complexMicrobiologyVirusEpitopeMiceViral ProteinsAntigenBetaherpesvirinaeVirologyCytotoxic T cellAnimalsCells CulturedMice Inbred BALB CImmunodominant Epitopesvirus diseasesHerpesviridae InfectionsFibroblastsbiology.organism_classificationVirologyAdoptive TransferDisease Models AnimalKineticsInsect ScienceImmunologybiology.proteinPathogenesis and ImmunityFemaleCD8
researchProduct

General application of Jäntti's method for the fast calculation of sorption equilibrium

2004

On the basis of a molecular model for adsorption kinetics Jantti introduced a method to calculate equilibriums shortly after a change of the pressure of the sorptive gas. In the present paper we show that this method is useful in many more situations than those intended originally.

Adsorption kineticsMolecular modelChemistryKineticsThermodynamicsAdsorption equilibriumSorptionPhysical and Theoretical ChemistryCondensed Matter PhysicsThermal analysis
researchProduct

Type of culture media does not affect embryo kinetics: a time-lapse analysis of sibling oocytes

2013

Are the morphokinetics of growing embryos affected by the type of culture media utilized?Morphokinetic parameters used for embryo selection are not affected between the two different concept culture media analyzed.Studies on the effect of culture media on human embryos have focused on evaluating different in-house and commercially available media as well as comparing outcomes among different commercial media. Nonetheless, the evaluation of embryo development in these studies was based on static observations and very little is known from a dynamic point of view.Prospective cohort study, October 2010 and April 2011.University-affiliated infertility center. Patients undergoing egg donation (n …

AdultAdolescentPregnancy RateBiologyTime-Lapse ImagingCohort StudiesAndrologyYoung AdultPregnancymedicineHumansEmbryo ImplantationProspective StudiesSiblingPregnancyOocyte DonationFifth thoracic vertebraRehabilitationObstetrics and GynecologyEmbryoAnatomymedicine.diseaseCulture MediaKineticsPregnancy rateBlastocystReproductive MedicineSpainOocyte donationOocytesPregnancy TwinEctogenesisFemaleBiomarkersHuman Reproduction
researchProduct

Study of T-cell activation in Type I diabetic patients and pre-Type I diabetic subjects by cytometric analysis: Antigen expression defectin vitro

1993

In Type I diabetes the observation of a decreased release of interleukin-2 (IL-2) and soluble IL-2 receptors by means of stimulated lymphocytes in vitro indicates that a primary immunoregulatory defect may be involved. To confirm this hypothesis we investigated the T-cell activation trend, evaluating the surface expression of IL-2 receptor (CD25), transferrin (CD71), HLA class II (DR), and CD69 phenotypes after in vitro stimulation with phytohemagglutinin (PHA; 1 and 10 micrograms/ml) and concanavalin A (12.5 micrograms/ml) in six newly diagnosed Type I diabetics and six islet cell- and insulin autoantibody-positive first-degree relatives. As controls were studied six long-standing Type I d…

AdultAntigens Differentiation T-LymphocyteCD4-Positive T-LymphocytesMaleInterleukin 2medicine.medical_specialtyTime FactorsAdolescentCD3 ComplexCD8 AntigensT-Lymphocytesmedicine.medical_treatmentT cellImmunologyTransferrin receptorBiologyLymphocyte ActivationAntigenAntigens CDInternal medicineDiabetes mellitusReceptors TransferrinmedicineHumansImmunology and AllergyLectins C-TypeIL-2 receptorPhytohemagglutininsReceptorInsulinReceptors Interleukin-2HLA-DR Antigensmedicine.diseaseAntigens Differentiation B-LymphocyteKineticsDiabetes Mellitus Type 1Endocrinologymedicine.anatomical_structureInterleukin-2Femalemedicine.drugJournal of Clinical Immunology
researchProduct

Disposition of azapropazone in chronic renal and hepatic failure.

1981

The disposition of azapropazone 600 mg i.v. was investigated in 6 healthy subjects, 13 patients with cirrhosis and 8 patients with renal failure. In healthy subjects the elimination half-life was 12.2±2.1 h (mean ± SD), the volume of distribution 10.6±3.31 and the total clearance was 597±135 ml·h−1. Renal clearance accounted for about 62% of the total clearance. The free fraction of azapropazone in the plasma was 0.0045±0.0006. The patients with cirrhosis were divided into Group I with modest and Group II with severe impairment of liver function. In Group I the total clearance of azapropazone was not significantly different from that in healthy subjects. There was a 2.5-fold increase in its…

AdultApazoneMalemedicine.medical_specialtyCirrhosisUrologyRenal functionchemistry.chemical_compoundPharmacokineticsInternal medicineMedicineHumansPharmacology (medical)AzapropazonePharmacologyVolume of distributionCreatininebusiness.industryTriazinesLiver DiseasesGeneral MedicineMiddle Agedmedicine.diseaseEndocrinologychemistryFree fractionCreatinineKidney Failure ChronicLiver functionbusinessmedicine.drugHalf-LifeEuropean journal of clinical pharmacology
researchProduct

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

2003

Pharmacokinetic and pharmacodynamic profiles of the rapid-acting insulin analogues lispro and aspart were compared in a randomized, double-blind crossover study of 20 fasting healthy men following a single subcutaneous injection. Either insulin lispro or aspart, 0.05 U/kg-body-weight, was injected subcutaneously and followed by determination of 5-h profiles of plasma glucose, serum C-peptide and insulin concentrations. Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l). For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRadioimmunoassayInsulin aspartSubcutaneous injectionEndocrinologyPharmacokineticsDouble-Blind MethodDiabetes mellitusInternal medicineInternal MedicinemedicineInsulin lisproHumansHypoglycemic AgentsInsulinInsulin AspartCross-Over StudiesInsulin LisproC-Peptidebusiness.industryInsulindigestive oral and skin physiologynutritional and metabolic diseasesGeneral Medicinemedicine.diseaseCrossover studyEndocrinologyPharmacodynamicsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Chronic Hyperinsulinemia Does Not Increase the Production Rate of High-Density Lipoprotein Apolipoprotein AI

2013

Objective— In vitro studies showed that insulin stimulates the production of apolipoprotein AI (apoAI). Thus, we hypothesized that chronic hyperinsulinemia could contribute to the increase in the production of high-density lipoprotein apoAI that is observed in metabolic syndrome. Approach and Results— We performed an in vivo kinetic study with stable isotope in 7 patients with insulinoma who showed hyperinsulinemia but no insulin resistance, 8 patients with insulin resistance, and 16 controls. Insulinemia was 3.1× ( P <0.01) higher in patients with insulinoma or insulin resistance than in controls in the fasting state and, respectively, 3.5× and 2.6× ( P <0.05) higher in the fed stat…

AdultBlood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentBiologyYoung Adultchemistry.chemical_compoundInsulin resistanceHigh-density lipoproteinHyperinsulinismInternal medicinemedicineHyperinsulinemiaHumansInsulinInsulinomaMetabolic SyndromeApolipoprotein A-IInsulinMiddle AgedPostprandial Periodmedicine.diseasePancreatic NeoplasmsKineticsEndocrinologychemistryCase-Control StudiesChronic DiseaseMultivariate AnalysisFemaleInsulinomaInsulin ResistanceMetabolic syndromeLipoproteins HDLCardiology and Cardiovascular MedicineHyperinsulinismLipoproteinArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy.

1991

A phase I clinical trial was conducted with recombinant human tumour necrosis factor alpha (rhTNF-alpha) in 62 patients with advanced malignancy refractory to previous standard therapy. rhTNF-alpha was given as a 30 min infusion twice a day at 6 h intervals. A total of 10 different dose levels was escalated in cohorts of 6 patients ranging from 2.5 to 200 micrograms/m2 twice a day for 5 days every second week for a total of 8 weeks followed by a 4-week observation period. Major side-effects of TNF-alpha therapy, seen in almost all patients studied, were fever and chills. As dose-limiting side-effects hypotension and liver toxicity were recorded in 4 of 5 patients treated with 200 micrograms…

AdultBlood PlateletsMalemedicine.medical_specialtyNecrosisAdolescentFeverPhases of clinical researchBlood PressureMalignancyGastroenterologyHemoglobinsLeukocyte CountPharmacokineticsRefractoryInternal medicineNeoplasmsmedicineLeukocytesHumansAgedbiologyDose-Response Relationship Drugbusiness.industryPlatelet CountTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryOncologybiology.proteinDrug EvaluationTumor necrosis factor alphaChillsFemaleAntibodymedicine.symptombusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Inhibition of dextromethorphan metabolism by moclobemide.

1998

This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine. The subjects received seven oral doses of 20 mg dextromethorphan at 4-h intervals over 2 days (1 and 2) and subsequently moclobemide (300 mg b.i.d.) for 9 days. On days 10 and 11, they received seven doses of 20 mg dextromethorphan in addition to moclobemide. During monotreatment and combined treatment, blood was collected on days 2 and 11, respectively, for determination of dextromethorphan and its demethylated metabolites using automat…

AdultCYP2D6animal structuresMonoamine Oxidase InhibitorsAdolescentMoclobemidePharmacologyDextromethorphanchemistry.chemical_compoundPharmacokineticsOral administrationDextrorphanMoclobemideMedicineHumansDrug InteractionsBiotransformationPharmacologybusiness.industryDextromethorphanDrug interactionAntidepressive AgentsDebrisoquinechemistryArea Under CurveBenzamidesbusinessmedicine.drugPsychopharmacology
researchProduct